Yildiz MZ, Peker B, Unal TC, Dolas I, Gulsever CI, Dolen D, Sonmez E, Aras Y, Aydoseli A, Sabanci PA, Sencer A, Izgi AN. The effect of halofuginone use on epidural fibrosis after spinal surgery: An animal experiment.
Turk Neurosurg 2023. [PMID:
38650558 DOI:
10.5137/1019-5149.jtn.42998-22.3]
[Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/25/2024]
Abstract
AIM
Epidural fibrosis (EF) can cause persistent low back pain after spinal surgery. Type I collagen is the main component of scar tissue formed after spinal surgery, and an antifibrotic agent is necessary for preventing fibrosis. Halofuginone is an antifibrotic agent that has an effect on type I collagen. Our study aimed to investigate the effectiveness of local halofuginone application for spinal EF after lumbar laminectomy in rats.
MATERIAL AND METHODS
Forty rats were equally divided into four groups (Groups I-IV; 10 rats in each group), and lumbar laminectomy was performed under general anesthesia. After laminectomy, Group I received saline (NaCl 0.9%) locally (control), Group II received spongostan, Group III received 0.5 mL of halofuginone-impregnated spongostan, and Group IV received 0.5 mL of halofuginone. Spongostan was used to prolong the exposure period of halofuginone. All rats were sacrificed after four weeks and evaluated according to histopathological criteria. A p-value of 0.05 was considered statistically significant.
RESULTS
Fibrosis was significantly lower in Group IV than in Group I (p 0.05). There was no significant difference in fibrosis between Group II/III and Group I. It was observed that spongostan increased fibrosis.
CONCLUSION
Halofuginone helps prevent EF after spinal surgery. However, further clinical and experimental studies are needed to assess its safety in humans.
Collapse